Information Statement about how Access to Nusinersen Treatment is Affected by COVID-19

08 January 2021

In April 2020, advice from clinical experts and discussions with the Patient Groups informed a statement from NICE, NHS England and NHS Improvement.

NICE have reviewed this and confirm that the flexibility and guidance in this statement remains in place.

It concerns those who are already receiving treatment and those who have not yet started treatment.

Read the April 2020 Statement

Please do contact us if you experience delays and difficulties with access to nusinersen.